Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis:: an open label study

被引:116
作者
Lahdenne, P [1 ]
Vähäsalo, P
Honkanen, V
机构
[1] Univ Helsinki, Hosp Children & Adolescents, Dept Paediat Rheumatol, FIN-00290 Helsinki, Finland
[2] Oulu Univ, Dept Paediat, Oulu 90029, Finland
[3] Rheumatism Fdn Hosp, Dept Paediat Rheumatol, SF-18120 Heinola, Finland
关键词
D O I
10.1136/ard.62.3.245
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To study infliximab and etanercept in the treatment of refractory juvenile idiopathic arthritis (JIA). Methods: In a non-randomised, prospective, open label study, 24 patients (mean age 10.2 years, range 3.3-16.3) with polyarticular JIA were treated with either infliximab (n = 14) or etanercept (n = 10). The patients had had active polyarthritis for at least one year and standard treatment had failed. Anti-tumour necrosis factor (TNF) treatment was added to the current drug treatment. Infliximab (3-4 mg/kg) was given intravenously at weeks 0, 2, and 6, and thereafter at 4 to 8 week intervals. Etanercept (0.4 mg/kg) was given subcutaneously twice a week. Improvement of the patients was assessed at 3, 6, and 12 months according to established JIA response criteria. Results: In intention to treat analyses, patients in both treatment groups improved significantly. ACR Paediatric 50 was achieved at 3, 6, and 12 months by 9/10 (90%), 8/9 (89%), and 8/9 (89%) patients with etanercept and by 8/12 (67%), 10/12 (83%), and 7/9 (78%) with infliximab, respectively. At 12 months, ACR Paediatric 75 was achieved by 67% of patients in both treatment groups. Five withdrawals due to adverse effects or lack of efficacy occurred in the infliximab group and one due to lack of compliance in the etanercept group. Conclusion: In this open label clinical study of active JIA, both infliximab and etanercept provided a significant rapid and sustained reduction in disease activity. Adequately powered randomised controlled trials are needed to elucidate the long term safety and efficacy of TNF modulators in the treatment of JIA.
引用
收藏
页码:245 / 247
页数:3
相关论文
共 15 条
[1]   Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial [J].
Chaudhari, U ;
Romano, P ;
Mulcahy, LD ;
Dooley, LT ;
Baker, DG ;
Gottlieb, AB .
LANCET, 2001, 357 (9271) :1842-1847
[2]  
Elliott MJ, 1997, BRIT J RHEUMATOL, V36, P589
[3]  
Giannini EH, 1997, ARTHRITIS RHEUM, V40, P1202
[4]   Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period [J].
Kietz, DA ;
Pepmueller, PH ;
Moore, TL .
ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (02) :171-173
[5]  
Kietz DA, 2001, J RHEUMATOL, V28, P360
[6]  
Lahdenne P, 2000, ARTHRITIS RHEUM, V43, pS381
[7]   Infliximab and methotrexate in the treatment of rheumatoid arthritis [J].
Lipsky, PE ;
van der Heijde, DMFM ;
St Clair, EW ;
Furst, DE ;
Breedveld, FC ;
Kalden, JR ;
Smolen, JS ;
Weisman, M ;
Emery, P ;
Feldmann, M ;
Harriman, GR ;
Maini, RN .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1594-1602
[8]   Etanercept in children with polyarticular juvenile rheumatoid arthritis. [J].
Lovell, DJ ;
Giannini, EH ;
Reiff, A ;
Cawkwell, GD ;
Silverman, ED ;
Nocton, JJ ;
Stein, LD ;
Gedalia, A ;
Ilowite, NT ;
Wallace, CA ;
Whitmore, J ;
Finck, BK .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (11) :763-769
[9]   Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:: a randomised phase III trial [J].
Maini, R ;
St Clair, EW ;
Breedveld, F ;
Furst, D ;
Kalden, J ;
Weisman, M ;
Smolen, J ;
Emery, P ;
Harriman, G ;
Feldmann, M ;
Lipsky, P .
LANCET, 1999, 354 (9194) :1932-1939
[10]   Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein [J].
Moreland, LW ;
Baumgartner, SW ;
Schiff, MH ;
Tindall, EA ;
Fleischmann, RM ;
Weaver, AL ;
Ettlinger, RE ;
Cohen, S ;
Koopman, WJ ;
Mohler, K ;
Widmer, MB ;
Blosch, CM .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (03) :141-147